The role of biologic response modifiers in the management of juvenile idiopathic arthritis associated uveitis: a review

References

• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology. international league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Bhat P, Goldstein DA. Pathophysiology of JIA-associated uveitis. Ocul Immunol Inflamm. 2014;22(5):414–423.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Griffin KW, Lehman TJ, et al. The importance of visual function in the quality of life of children with uveitis. J AAPOS. 2010;14(2):163–168.
   PubMed Web of Science ®Google Scholar
• Calandra S, Gallo MC, Consolaro A, et al. Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. J Rheumatol. 2014;41(7):1416–1425.
   PubMed Web of Science ®Google Scholar
• Ezzahri M, Amine B, Rostom S, et al. The uveitis and its relationship with disease activity and quality of life in Moroccan children with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32(9):1387–1391.
   PubMed Web of Science ®Google Scholar
• Sabri K, Saurenmann RK, Silverman ED, et al. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12(6):539–545.
   PubMed Web of Science ®Google Scholar
• Bolt IB, Cannizzaro E, Seger R, et al. Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland. J Rheumatol. 2008;35(4):703–706.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015–1019.
   PubMed Web of Science ®Google Scholar
• Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120(1):186–192.
   PubMed Web of Science ®Google Scholar
• Walscheid K, Hennig M, Heinz C, et al. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis. Invest Ophthalmol Vis Sci. 2014;55(6):3447–3453.
   PubMed Web of Science ®Google Scholar
• Foster CS, Kothari S, Anesi SD, et al. The ocular immunology and uveitis foundation (OIUF) preferred practice patterns of uveitis management. Surv Ophthalmol. 2016 Jan–Feb;61(1):1–17.
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M:. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372–377.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–796.
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following Etanercept treatment. Curr Eye Res. 2010;35:751–756.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–1150.
   PubMed Web of Science ®Google Scholar
• Tarkiainen M, Tynjala P, Vahasalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology. 2014;54(7):1170–1176.
   PubMed Web of Science ®Google Scholar
• Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (ADJUVITE). ClinicalTrials.gov U.S. National Institutes of Health. Jan 2016. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01385826
   Google Scholar
• William M, Faez S, Papaliodis GN, et al. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2:231–233.
   PubMedGoogle Scholar
• Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31(1):90–91.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390–1394.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015 Apr;42(4):706–711.
   PubMed Web of Science ®Google Scholar
• Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009 Nov;148(5):696–703.e1.
   Web of Science ®Google Scholar
• Roth JA. Enhancement of nonspecific resistance to bacterial infection by biologic response modifiers. In J A Roth. 1988;329–342. Virulence mechanisms of biologic pathogens.
   Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34(4):365–374.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Chicha L, Gregorio A, et al. Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue. Rheumatology. 2007;46:657–665.
   PubMed Web of Science ®Google Scholar
• Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. Am J Ophthalmol. 2013;155:134–142.
   PubMed Web of Science ®Google Scholar
• Silva LC, Ortigosa LC, Benard G:. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–833.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014 Apr;22(2):90–95.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology. 2005;44:1008–1011.
   PubMed Web of Science ®Google Scholar
• Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2015 Dec 31;pii:kev434. [ Epub ahead of print].
   Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21(1):19–27.
   PubMed Web of Science ®Google Scholar
• Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment -resistant uveitis. Arthritis Rheum. 2001;44(6):1411–1415.
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001 Jun;45(3):252–257.
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–864.
   PubMed Web of Science ®Google Scholar
• Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors. J Rheumatol. 2013;40(8):1394–1403.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314.
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144:844–849.
   PubMed Web of Science ®Google Scholar
• Shakoor A 1, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96–101.
   PubMed Web of Science ®Google Scholar
• García-De-Vicuña C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
   PubMed Web of Science ®Google Scholar
• Torre FL, Cattalini M, Teruzzi B, et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res Notes. 2014;7:316.
   PubMedGoogle Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol. 2013;40:74–79.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1601–1606.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
   PubMed Web of Science ®Google Scholar
• Hardwick B. SYCAMORE Trial Summary. 15 Sep 2015. Available from: http://www.sycamoretrial.org.uk/summary.html
   Google Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892.e3–4.
   PubMedGoogle Scholar
• Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology. 2011;118(1):223–224.
   PubMed Web of Science ®Google Scholar
• Iwahashi C, Fujimoto M, Nomura S, et al. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: comparison with blockade of interleukin-6. Exp Eye Res. 2015;140:53–64.
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825.
   PubMed Web of Science ®Google Scholar
• Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63(2):307–308.
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297–30.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014 Apr;22(2):155–157.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?. J Rheumatol. 2012;39:1294–1295.
   PubMed Web of Science ®Google Scholar
• Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis. ClinicalTrials.gov U.S. National Institutes of Health. Jan 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01603355
   Google Scholar
• Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015 Sep 11;9:1697–1702.
   PubMed Web of Science ®Google Scholar
• Pardeo M 1, Pires Marafon D 2, Insalaco A 2, et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol. 2015 Aug;42(8):1523–1527.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A 1, Michels H, Schumacher C, et al, German ophthalmological society; society for childhood and adolescent rheumatology; German Society for Rheumatology. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012 May;32(5):1121–1133.
   PubMed Web of Science ®Google Scholar
• Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010 Apr;18(2):116–146.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn J, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009 Jul 3;339:b2480.
   PubMedGoogle Scholar
• Kok VC, Horng JT, Huang JL, et al. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis. BMC Cancer. 2014 Aug 29;14:634.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatology (Oxford). 2014 Jun;53(6):968–974.
   PubMed Web of Science ®Google Scholar
• Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Reports. 2014;6:41.
   PubMedGoogle Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
   PubMedGoogle Scholar